Aligos Therapeutics presented positive long-term data at the EASL Congress 2026 showing that pevifoscorvir sodium monotherapy reduces the cccDNA reservoir in chronic hepatitis B patients, potentially enabling functional cure. About 40% of treated HBeAg+ patients had significant reductions in HBsAg, making them eligible for further antisense oligonucleotide (ASO) therapy. The combination of pevifoscorvir sodium with ASO ALG-170675 showed additive to synergistic antiviral effects, suggesting pevifoscorvir sodium could replace current standard treatments and play a key role in functional cure regimens. Further clinical development and regulatory progress are anticipated.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
